Current Radiopharmaceuticals
Title:Meet Our Editorial Board Member
Volume: 10 Issue: 1
Author(s): Peter J. H. Scott
Affiliation:
Export Options
About this article
Cite this article as:
Scott J. H. Peter, Meet Our Editorial Board Member, Current Radiopharmaceuticals 2017; 10 (1) . https://dx.doi.org/10.2174/187447101001170308175951
DOI https://dx.doi.org/10.2174/187447101001170308175951 |
Print ISSN 1874-4710 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4729 |
Article Metrics

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Multiple Roles for Glycogen Synthase Kinase-3 as a Drug Target in Alzheimers Disease
Current Drug Targets Primary Progressive Aphasia-Defining Genetic and Pathological Subtypes
Current Alzheimer Research Mechanism of Tau-Induced Neurodegeneration in Alzheimer Disease and Related Tauopathies
Current Alzheimer Research Current Options in the Treatment of Mitochondrial Diseases
Recent Patents on CNS Drug Discovery (Discontinued) FDG PET/MR Imaging in Major Neurocognitive Disorders
Current Alzheimer Research Pin1: A New Outlook in Alzheimers Disease
Current Alzheimer Research The Brainstem Tau Cytoskeletal Pathology of Alzheimer’s Disease: A Brief Historical Overview and Description of its Anatomical Distribution Pattern, Evolutional Features, Pathogenetic and Clinical Relevance
Current Alzheimer Research Molecular Genetics of Early- and Late-Onset Alzheimer’s Disease
Current Gene Therapy PET Radiotracers for Molecular Imaging in Dementia
Current Radiopharmaceuticals Davunetide: Peptide Therapeutic in Neurological Disorders
Current Medicinal Chemistry Inflammation in Parkinsons Diseases and Other Neurodegenerative Diseases: Cause and Therapeutic Implications
Current Pharmaceutical Design Applying Epigenetics to Alzheimer’s Disease via the Latent Early–life Associated Regulation (LEARn) Model
Current Alzheimer Research COMMENTARY: Magnetic Resonance Techniques Applied to Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Cysteine Network (CYSTEINET) Dysregulation in Parkinson’s Disease: Role of N-acetylcysteine
Current Drug Metabolism Human Platelet Acetylcholinesterase Inhibition by Cyclophosphamide: A Combined Experimental and Computational Approach
CNS & Neurological Disorders - Drug Targets Editorial (Thematic Issue: Immunophilins, Protein Chemistry and Cell Biology of a Promising New Class of Drug Targets – Part II)
Current Molecular Pharmacology Impulse Control Disorders in Parkinson’s Disease: A Review
Current Psychiatry Reviews Co-Enzyme Q10 to Treat Neurological Disorders: Basic Mechanisms, Clinical Outcomes, and Future Research Direction
CNS & Neurological Disorders - Drug Targets Protein Kinase CK2 in Human Diseases
Current Medicinal Chemistry Relevant Modulation by Ferrous Ions of N-Methyl-D-Aspartate Receptors in Ischemic Brain Injuries
Current Neurovascular Research